Quick Answer
Regen BioPharma Inc reported Stockholders Equity of -$6.28 million for fiscal year 2025.
Regen BioPharma Inc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$6.28M | -20.4% |
| 2024 | -$5.22M | -2.2% |
| 2023 | -$5.10M | -1.5% |
| 2023 | -$5.03M | -2.0% |
| 2023 | -$4.93M | -0.9% |
| 2022 | -$4.88M | +39.2% |
| 2022 | -$8.04M | +3.8% |
| 2022 | -$8.35M | +89.1% |
| 2022 | -$76.75M | -686.7% |
| 2021 | -$9.76M | +27.7% |
| 2021 | -$13.49M | -8.7% |
| 2021 | -$12.41M | -144.8% |
| 2021 | -$5.07M | +9.1% |
| 2020 | -$5.58M | +23.9% |
| 2020 | -$7.33M | +14.3% |
| 2020 | -$8.56M | +27.3% |
| 2020 | -$11.77M | -52.9% |
| 2019 | -$7.70M | +29.4% |
| 2019 | -$10.91M | +14.7% |
| 2019 | -$12.79M | -45.0% |
| 2019 | -$8.82M | -1.8% |
| 2018 | -$8.66M | +5.0% |
| 2018 | -$9.12M | -6.5% |
| 2018 | -$8.57M | -0.2% |
| 2018 | -$8.55M | -9.6% |
| 2017 | -$7.80M | -48.5% |
| 2017 | -$5.25M | -33.7% |
| 2017 | -$3.93M | -186.4% |
| 2017 | -$1.37M | -862.8% |
| 2016 | -$142.4K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$6.57M | -15.7% | -4.6% |
| September 30, 2025 | -$6.28M | -20.4% | -8.0% |
| June 30, 2025 | -$5.82M | -12.8% | -2.1% |
| March 31, 2025 | -$5.70M | -10.1% | -0.3% |
| December 31, 2024 | -$5.68M | -8.3% | -8.8% |
| September 30, 2024 | -$5.22M | -2.2% | -1.2% |
| June 30, 2024 | -$5.16M | -2.6% | +0.4% |
| March 31, 2024 | -$5.18M | -5.0% | +1.3% |
- Regen BioPharma Inc showed a decrease of -20.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2016–2025 period, Regen BioPharma Inc’s stockholders equity has declined by 4310.4% (from -$142.4 thousand to -$6.28 million).
- The most recent figure is from Regen BioPharma Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: